Filing Details

Accession Number:
0000899140-23-000696
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-30 19:01:04
Reporting Period:
2023-05-25
Accepted Time:
2023-05-30 19:01:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080014 Innoviva Inc. INVA Pharmaceutical Preparations (2834) 943265960
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1361754 J Alexander Denner C/O Sarissa Capital Management Lp
680 Steamboat Road
Greenwich CT 06830
No No No No
1577524 Sarissa Capital Management Lp 680 Steamboat Road
Greenwich CT 06830
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.01 Per Share Acquisiton 2023-05-25 50,000 $13.09 7,050,000 No 4 P Indirect See footnotes
Common Stock, Par Value $0.01 Per Share Acquisiton 2023-05-26 30,000 $13.12 7,080,000 No 4 P Indirect See footnotes
Common Stock, Par Value $0.01 Per Share Acquisiton 2023-05-30 120,000 $13.01 7,200,000 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
No 4 P Indirect See footnotes
No 4 P Indirect See footnotes
Footnotes
  1. On May 25, 2023, the Reporting Persons acquired 50,000 shares of Common Stock at a weighted average price of $13.0866 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.015 to $13.14 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
  2. On May 26, 2023, the Reporting Persons acquired 30,000 shares of Common Stock at a weighted average price of $13.1243 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.011 to $13.14 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
  3. On May 30, 2023, the Reporting Persons acquired 120,000 shares of Common Stock at a weighted average price of $13.0054 per share. The shares were purchased in multiple open market transactions at prices ranging from $12.93 to $13.125 per share, inclusive. The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
  4. Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the "Sarissa Funds") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America ("Dr. Denner"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions.
  5. Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein.